利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

10 条记录 (耗时 0.028 秒)

    Synergistic anti-CD47 therapy for hematologic cancers
    6.
    发明授权
    Synergistic anti-CD47 therapy for hematologic cancers 有权
    协同抗CD47治疗血液癌

    公开(公告)号：US08758750B2

    公开(公告)日：2014-06-24

    申请号：US13394060

    申请日：2010-09-15

    申请人： Irving L. Weissman ,  Ravindra Majeti ,  Arash Ash Alizadeh ,  Mark P. Chao

    发明人： Irving L. Weissman ,  Ravindra Majeti ,  Arash Ash Alizadeh ,  Mark P. Chao

    IPC分类号： A61K39/395 ,  A61K39/00

    CPC分类号： C07K16/2803 ,  A61K39/39558 ,  A61K51/1093 ,  A61K2039/507 ,  C07K16/2887 ,  C07K2317/732 ,  C07K2317/734 ,  C07K2317/77

    摘要： Methods are provided for treatment of hematologic cancers, particularly lymphomas and leukemias, including without limitation myelogenous and lymphocytic leukemias. A combination of antibodies specific for CD47; and specific for a cancer associated cell surface marker are administered to the patient, and provide for a synergistic decrease in cancer cell burden. The combination of antibodies may comprise a plurality of monospecific antibodies, or a bispecific or multispecific antibody. Markers of interest include without limitation, CD20, CD22, CD52, CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; and HAVCR2.

    摘要翻译： 提供了用于治疗血液癌，特别是淋巴瘤和白血病的方法，包括但不限于骨髓性和淋巴细胞性白血病。 CD47特异性抗体的组合; 并向癌症相关细胞表面标志物特异性给予患者，并提供癌细胞负担的协同降低。 抗体的组合可以包含多个单特异性抗体，或双特异性或多特异性抗体。 感兴趣的标记包括但不限于CD20，CD22，CD52，CD33; CD96; CD44; CD123; CD97; CD99; PTHR2; 和HAVCR2。

    HUMAN HEMATOPOIETIC MULTIPOTENT PROGENITOR CELLS
    9.
    发明申请
    HUMAN HEMATOPOIETIC MULTIPOTENT PROGENITOR CELLS 审中-公开
    人类HEMATOPOIETIC MULTIPOTENT PROGENITOR CELLS

    公开(公告)号：US20090191164A1

    公开(公告)日：2009-07-30

    申请号：US12353098

    申请日：2009-01-13

    申请人： Ravindra Majeti ,  Irving L. Weissman

    发明人： Ravindra Majeti ,  Irving L. Weissman

    IPC分类号： A61K35/12 ,  C12N5/08 ,  C12Q1/68 ,  C12Q1/02 ,  A61P37/00

    CPC分类号： C12N5/0647 ,  A61K35/28 ,  A61K35/51 ,  G01N15/042 ,  G01N33/5073 ,  G01N2015/149 ,  G01N2500/00

    摘要： A substantially enriched human multipotent progenitor cell population is provided, which is characterized as a progenitor cell capable of giving rise to the multipotent lineage but which lacks certain long-term self-renewal properties of the hematopoietic stem cell. Methods are provided for the isolation and culture of these cells. The cell enrichment methods employ reagents that specifically recognize CD34, CD38, CD90 and CD45RA, in conjunction with lineage specific markers. These cells give rise to all types of hematopoietic cells, e.g. myeloid and lymphoid cells, in vivo.

    摘要翻译： 提供了一种基本上富集的人多能祖细胞群，其特征在于能够产生多能谱系但缺乏造血干细胞某些长期自我更新性质的祖细胞。 提供了用于分离和培养这些细胞的方法。 细胞富集方法使用特异性识别CD34，CD38，CD90和CD45RA的试剂，与谱系特异性标记物结合。 这些细胞产生所有类型的造血细胞，例如， 骨髓和淋巴细胞，体内。

    Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature
    10.
    发明申请
    Prediction of Clinical Outcome in Hematological Malignancies Using a Self-Renewal Expression Signature 审中-公开
    使用自我更新表达签名预测血液恶性肿瘤的临床结果

    公开(公告)号：US20140148351A1

    公开(公告)日：2014-05-29

    申请号：US13825511

    申请日：2011-09-28

    申请人： Arash Ash Alizadeh ,  Ravindra Majeti ,  Andrew J. Gentles

    发明人： Arash Ash Alizadeh ,  Ravindra Majeti ,  Andrew J. Gentles

    IPC分类号： C12Q1/68

    CPC分类号： C12Q1/6886 ,  C12Q2600/158

    摘要： Methods, compositions, and kits are provided for providing a diagnosis, a prognosis, or a prediction of responsiveness to a therapy for a patient with a hematological malignancy. In practicing the subject methods, the expression level of at least one leukemia stem cell (LSC) genes in a tissue sample is assayed to obtain an LSC expression representation. The LSC expression representation is then employed to determine if an individual has a hematological malignancy, to provide a prognosis to a patient with a hematological malignancy, and/or to provide a prediction of the responsiveness of a patient with a hematological malignancy to a therapy. Also provided are screening methods for identifying novel therapies for patients with a hematological malignancy, and compositions and kits for use in these screening methods.

    摘要翻译： 提供了方法，组合物和试剂盒，用于提供对具有血液恶性肿瘤的患者的治疗的反应性的诊断，预后或预测。 在实施本发明方法中，测定组织样品中至少一种白血病干细胞（LSC）基因的表达水平以获得LSC表达。 然后使用LSC表达表示来确定个体是否具有血液恶性肿瘤，为具有血液恶性肿瘤的患者提供预后，和/或提供患者对于治疗有血液恶性肿瘤的反应性的预测。 还提供了用于鉴定具有血液恶性肿瘤的患者的新疗法的筛选方法，以及用于这些筛选方法的组合物和试剂盒。